港股异动 | 维升药业-B(02561)涨超5% 治疗软骨发育不全药物那韦培肽完成中国2期临床试验

智通财经2025-05-13

智通财经APP获悉，维升药业-B(02561)涨超5%，截至发稿，涨5.39%，报46.9港元，成交额217.21万港元。消息面上，5月12日，维升药业宣布其在研的用于治疗软骨发育不全(achondroplasia, ACH)的那韦培肽(Navepegritide, TransCon CNP)中国2期临床试验已全部顺利完成(包括52周双盲治疗期以及52周开放标签扩展阶段)，并于近期在国家药监局“...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2535946327?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-13 14:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535946327","market":"us","top_or_hot":-1,"title":"港股异动 | 维升药业-B(02561)涨超5% 治疗软骨发育不全药物那韦培肽完成中国2期临床试验","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，维升药业-B(02561)涨超5%，截至发稿，涨5.39%，报46.9港元，成交额217.21万港元。消息面上，5月12日，维升药业宣布其在研的用于治疗软骨发育不全(achondroplasia, ACH)的那韦培肽(Navepegritide, TransCon CNP)中国2期临床试验已全部顺利完成(包括52周双盲治疗期以及52周开放标签扩展阶段)，并于近期在国家药监局“...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1292438.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 维升药业-B(02561)涨超5% 治疗软骨发育不全药物那韦培肽完成中国2期临床试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 维升药业-B(02561)涨超5% 治疗软骨发育不全药物那韦培肽完成中国2期临床试验\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-13 14:54 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1292438.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，维升药业-B(02561)涨超5%，截至发稿，涨5.39%，报46.9港元，成交额217.21万港元。消息面上，5月12日，维升药业宣布其在研的用于治疗软骨发育不全(achondroplasia, ACH)的那韦培肽(Navepegritide, TransCon CNP)中国2期临床试验已全部顺利完成(包括52周双盲治疗期以及52周开放标签扩展阶段)，并于近期在国家药监局“...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1292438.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03347","symbol_name":"泰格医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1292438.html","article_id":"2535946327","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535946327","pubTimestamp":1747119240,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，维升药业-B涨超5%，截至发稿，涨5.39%，报46.9港元，成交额217.21万港元。消息面上，5月12日，维升药业宣布其在研的用于治疗软骨发育不全的那韦培肽中国2期临床试验已全部顺利完成，并于近期在国家药监局“药物临床试验登记与信息公示平台”登记临床试验结果信息。据悉，那韦培肽中国2期临床试验针对中国2至10岁ACH患儿，采用每周一次皮下给药的方式，旨在安全治疗剂量下持续提供活性CNP。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"03347":"泰格医药","02561":"维昇药业-B","BK1583":"高瓴概念","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK1161":"生物科技"},"translate_title":"Hong Kong stock market changes Weisheng Pharmaceutical-B (02561) rose more than 5% Navirpetide, a drug for treating achondroplasia, completed phase 2 clinical trial in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1,"03347":1},"content_text":"智通财经APP获悉，维升药业-B(02561)涨超5%，截至发稿，涨5.39%，报46.9港元，成交额217.21万港元。消息面上，5月12日，维升药业宣布其在研的用于治疗软骨发育不全(achondroplasia, ACH)的那韦培肽(Navepegritide, TransCon CNP)中国2期临床试验已全部顺利完成(包括52周双盲治疗期以及52周开放标签扩展阶段)，并于近期在国家药监局“药物临床试验登记与信息公示平台”登记临床试验结果信息。据悉，那韦培肽中国2期临床试验针对中国2至10岁ACH患儿，采用每周一次皮下给药的方式，旨在安全治疗剂量下持续提供活性CNP。此外，维升药业近期就公司基本面及核心产品管线的发展状况与投资者进行了深入交流，其中提到，那韦培肽是潜在的相关地区儿童软骨发育不全的同类首创疾病修复疗法，目前国内尚无同类产品获批，且无其他公司在进行相关研发。公司计划将该药物的适应症设计覆盖从儿童诊断开始至15岁的整个生长发育阶段。鉴于患者治疗周期长达十几年，且市场独占性明显，该产品未来有望实现数亿元的年销售额。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2535946327","isCrawlerRequest":true}